- Home
- NAT vs QURE Comparison
NAT vs QURE Comparison
Compare NAT & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAT | QURE |
|---|---|---|
| Founded | 1995 | 1998 |
| Country | Bermuda | Netherlands |
| Employees | N/A | 248 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1997 | 2013 |
Fundamental Metrics
Financial Performance| Metric | NAT | QURE |
|---|---|---|
| Price | $5.42 | $24.16 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $4.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 2.9M | 1.9M |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 8.50% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $77.72 | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | $525.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.55 | $8.73 |
| 52 Week High | $6.34 | $71.50 |
Technical Indicators
Market Signals| Indicator | NAT | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 56.28 |
| Support Level | $5.39 | $21.16 |
| Resistance Level | $6.30 | $25.66 |
| Average True Range (ATR) | 0.19 | 2.21 |
| MACD | -0.04 | -0.31 |
| Stochastic Oscillator | 16.34 | 44.79 |
Price Performance
Historical ComparisonAbout NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.